Dexcom
DXCM10.0K
$87.73
▼ 2.01%
None(1.8%)
5y ago · Mar 9, 2021
1
5y ago · CA · 178 affected
Low
AI Layoff Impact Summary
AI-poweredDexcom announced layoffs 5y ago (Mar 9, 2021), affecting 178 employees (1.8% of workforce). WARN filings indicate 1 active notices. Low risk — company appears stable.
All Posts
Everything in one feed
The vibe shift at HQ is real
I’ve been at Dexcom for over four years, and I’ve never seen the office this quiet. The energy used to be electric, but lately, it feels like everyone is walking on eggshells. We just had another leadership shakeup, and nobody is explaining why. The transparency that we used to pride ourselves on has basically vanished, replaced by generic 'corporate speak' emails that say absolutely nothing of substance. I’m starting to see people update their LinkedIn profiles at a rate I haven't seen since the last big market correction. It’s hard not to feel like the other shoe is about to drop. Has anyone heard anything specific, or are we all just waiting for the axe to fall? I’m seriously considering looking for an exit strategy now instead of waiting to be blindsided. The uncertainty is worse than the actual news at this point.
Is the G7 ramp-up actually slowing down?
I’ve been hearing a lot of chatter lately about our manufacturing output targets being adjusted for Q4. Management keeps pushing the 'record growth' narrative in the town halls, but the internal vibes feel different. My manager has been extremely tight-lipped about headcount planning for next year, which is a major departure from how we usually operate. Usually, we’re hiring like crazy to keep up with the scale, but I’ve noticed several open reqs in my department have been pulled or frozen over the last two weeks. Is anyone else noticing this in their respective business units, or am I just reading into the normal seasonal slowdown? It feels like we are pivoting to 'efficiency' mode, which we all know is just code for something else. Would love to hear if others are seeing the same hiring freezes or if your leads are acting strange during 1:1s.
Dexcom - Beyond the hype, what's the reality for employees?
So, Dexcom's always been the darling of the CGM world, right? G7 launch was huge, tons of press. But I'm wondering what that actually means for the day-to-day. Is the growth translating into sustainable roles, or are we seeing the usual pressures that come with rapid expansion – like increased workload, shifting priorities, maybe even some 'right-sizing' down the line? Just trying to get a pulse on the ground truth beyond the investor calls and marketing. Anyone willing to share their unfiltered experience?
Dexcom - Rumblings or just noise?
Hey everyone, been seeing a lot of chatter across different platforms about potential shifts at Dexcom. Nothing concrete, of course, but the general vibe feels a bit... uncertain. Anyone else picking up on this? Been here a few years and it's usually felt pretty solid, but lately, there's a low hum of 'what ifs'. Are people hearing anything specific, or is this just the usual market anxiety bleeding into things? Curious to hear if others in different departments are feeling the same or if it's isolated.
Dexcom: Anyone else feeling unease about stability?
Lately, there's been this undercurrent of uncertainty that I can't quite shake. It's not one specific thing, but a collection of small signs. You know, the usual 'things that make you go hmmm'. Heard a few whispers, saw some internal reorganizations that seemed a bit more than routine. The market's been tough for MedTech lately, and while Dexcom is a strong player, nobody's completely immune. I'm trying not to jump to conclusions, but I'm wondering if anyone else is picking up on similar vibes. Are there any teams feeling the squeeze more than others? Any new hires being put on hold, or projects being reassessed? Just looking to see if others are feeling this quiet tension or if I'm just overthinking things based on external factors. Sharing thoughts, not making accusations. Stay safe out there.
Dexcom G7: What's the real impact on the ground?
Hey everyone, been seeing a lot of chatter about the G7 launch and how it's playing out. I'm in a role where I'm seeing some of the downstream effects, and honestly, it feels a bit...mixed? On one hand, the tech is definitely an improvement, and we're hearing positive feedback from users who've made the switch. But on the other, the rollout hasn't been perfectly smooth, and I'm wondering if this is creating any internal pressure. Are sales teams feeling the heat? Is R&D already deep into the next big thing or are they still refining G7? Curious to hear from anyone directly involved or seeing the impacts – sales, marketing, engineering, even operations. How's G7 truly landing, and what does it mean for our pipeline and overall company direction? Trying to get a clearer picture beyond the official comms.
Dexcom: Thoughts on the recent G7 rollout and future product strategy?
Curious to hear what people think about the G7 rollout. Seemed like a bit of a bumpy start, but are we seeing positive traction now? More importantly, what's the general feeling about the pipeline beyond G7? I know there's always a lot of R&D going on, but sometimes it feels like the focus can shift based on market pressures or competitive moves. Are there any exciting projects or areas that are getting a lot of internal buzz and investment? Conversely, are there any areas that seem to be getting deprioritized or seeing less attention than before? Just trying to understand where the company's strategic focus really lies for the next few years, especially in light of the general medtech landscape. Any insights from those closer to product development or strategy would be greatly appreciated.
Dexcom: Layoff rumors swirling?
Hey everyone, been seeing some chatter on here and other platforms about potential layoffs at Dexcom. Nothing concrete has surfaced, but the whispers are getting louder. Has anyone heard anything specific or noticed any unusual activity internally? Like unusual team reorgs, budget cuts, or even just a weird vibe in meetings? I'm trying to get a sense of whether this is just internet noise or if there's actually something to it. My team hasn't said anything directly, but there's definitely a bit of an anxious energy going around. Wondering if anyone has seen more direct signs, like hiring freezes being extended, or if performance reviews are suddenly getting way more critical. Trying to prepare myself mentally if something does happen. Let me know what you're seeing or hearing, even if it's just a gut feeling.
Dexcom: What's the internal sentiment on the market and our pipeline?
Just wanted to gauge the general feeling around Dexcom right now. With the broader economic climate and competition heating up in the CGM space, I'm wondering how everyone internally feels about our current product pipeline and overall market position. Are people confident we're still leading the pack, or are there concerns about competitors catching up or even surpassing us? It feels like there's a lot of pressure to perform, and I'm curious if that's translating into more scrutiny on budgets or performance reviews across the board. Curious to hear thoughts from various teams.
Dexcom: Anyone else seeing hiring freezes or project slowdowns?
Hey all, longtime lurker here. Been at Dexcom for a few years and things have felt... different lately. Heard whispers about a hiring freeze in a few departments, and some projects that were full steam ahead seem to be slowing down considerably or getting re-scoped. My manager is being pretty tight-lipped, just saying we're 'optimizing resources.' Anyone else picking up on this? Not hearing outright layoff rumors, but the vibe is definitely shifting from growth mode. Curious if this is widespread or just in my area. Anyone in R&D, Sales, or Operations seeing similar trends?
Dexcom: Feeling the pinch - layoffs or just reorganization?
Is it just me, or has the vibe at Dexcom felt a little tense recently? Seeing a lot of chatter about efficiency and restructuring, and while nothing official has been announced, there's a definite undercurrent of 'what's next.' I've heard whispers about certain departments being more affected than others, but it's all very unofficial. Trying to gauge if this is leading towards actual layoffs or if it's just a typical reorganization phase. My manager is being pretty tight-lipped, which doesn't help. Anyone else in a similar boat or have any concrete information they can share (without breaking NDAs, obviously)? Just trying to prepare myself mentally and professionally for whatever might be coming. It's a stressful time trying to figure out where things stand.
Dexcom: Q4 performance and team structures?
Hey everyone, Just wanted to open up a discussion. With the recent Q4 earnings call and the ongoing integration of new product lines (like the G7 updates), I'm curious to hear what others are seeing on the ground. Has anyone noticed any significant shifts in team structures or project priorities lately? I feel like things have been a bit up in the air, and I'm trying to get a pulse on how these broader company movements might be impacting individual teams and roles. It’s hard to tell if it’s just normal business cycles or something more. Anyone else feeling this uncertainty or have insights into what's driving these potential changes? Just trying to get a better understanding of the landscape. Appreciate any thoughts or observations.
Dexcom: G7 rollout & employee impact?
With the G7 seemingly gaining traction, I'm wondering about the internal implications. We're all working hard, but sometimes it feels like we're spinning our wheels on legacy products while the focus shifts. Has anyone seen significant changes in workload or team structure related to the G7 push? I'm not talking layoffs specifically, but more about resource allocation, project priorities, and whether our current roles are aligning with the company's future direction. It feels like a critical juncture for Dexcom, and understanding how that impacts us on the ground would be really helpful. Any insights from those closer to the G7 development or market strategy would be appreciated.
Dexcom: Anyone else feeling the pressure?
Hey everyone, been working at Dexcom for a bit now and lately, there's just this underlying tension. No official word on anything, but the vibes are… off. My team's been stretched thin, and projects seem to be getting re-prioritized constantly. Heard some whispers about budget reviews and restructuring, but nothing concrete. Anyone else picking up on this? Is it just me or is there something brewing that we're not being told? Trying not to panic, but the lack of clarity is making it tough to stay focused. Wondering if it's a widespread thing across departments or if some areas are feeling it more than others. Curious to hear if anyone has any intel or just shared feelings.
Dexcom: Q4 outlook and potential headcounts?
With Q4 earnings season approaching, I'm starting to think about the company's overall trajectory. We've seen some significant market shifts recently, and while Dexcom seems to be holding its own, I'm wondering if leadership is anticipating any significant headcount adjustments either way. Sometimes growth phases can lead to unexpected cuts if certain projects don't pan out or if there's a strategic pivot. Conversely, continued success could mean more investment in people. Does anyone have a sense of what the internal vibe is regarding potential hiring freezes or, conversely, planned expansion for the next fiscal year? Trying to get a feel for the landscape beyond the immediate product news.
Dexcom: Any word on G7 ramp-up and its impact?
Hey everyone, been seeing a lot of chatter about the G7 rollout and the continued success of G6. It feels like things are picking up steam, which is great, but I'm also curious about how that's translating to staffing. Are departments seeing increased hiring to support the new product and increased demand? Or is it more of a 'do more with less' situation across the board? I've heard some murmurs here and there but nothing concrete. Just trying to gauge the general sentiment and see if anyone has insights into whether the growth is leading to more opportunities or if things are staying tight. Curious to hear what others are observing, especially in R&D, manufacturing, and sales.
Dexcom: Thoughts on recent product launches and staffing levels?
Just finished reading about the latest G7 updates and the upcoming product roadmap. Exciting stuff, genuinely. But it also got me thinking about our current staffing levels across different departments. With these ambitious goals, are we adequately resourced? Or is anyone else seeing signs of projects being stretched thin due to personnel constraints? I'm not talking about layoffs directly, but more about the efficiency and potential strain on existing teams. Sometimes, a company might indirectly 'right-size' by slowing down new hires or reallocating resources, which can feel similar. Has anyone been involved in recent hiring discussions or seen any departmental shifts that might indicate something? Just trying to understand how the company is balancing growth ambitions with current operational realities. Open to any thoughts or observations.
Dexcom: Anyone else feeling uneasy about the market right now?
Hey all, been at Dexcom for a few years now, mostly in R&D. Love the company and the mission, but lately, I've been getting a bit of an uneasy feeling with all the broader market news and especially some of the chatter in other medtech companies. I haven't heard anything concrete about layoffs at Dexcom itself, no official announcements, no suspicious all-hands meetings. It's more of a gut feeling based on economic indicators and some of the hiring freezes or slowdowns I've seen mentioned elsewhere in the industry. Anyone else in a similar boat? Just trying to gauge the general sentiment. Is it just me being paranoid, or are others noticing anything? Curious to hear if anyone has any intel, even if it's just anecdotal. Trying to stay positive but also want to be prepared. What's the vibe on the ground?
Dexcom: Layoff rumors or just market jitters?
Is it just me, or has the vibe at Dexcom shifted slightly recently? I'm not seeing any official announcements or anything concrete, but there's this low hum of uncertainty that feels a bit familiar from past downturns in other companies. Is anyone else picking up on this? Are there specific teams or departments that seem to be under more scrutiny? Could be nothing, could be pre-emptive cost-cutting. I know Dexcom is in a strong position generally, but the broader economic climate is definitely making people antsy. Would be great to hear if others are feeling this or if it's just my own paranoia amplified by reading too much on these forums. Anything concrete or even speculative is welcome.
Dexcom: Any whispers on the horizon?
Hey everyone, been seeing a lot of chatter on other medtech forums about potential reshuffling and belt-tightening across the industry. Wondering if anyone here at Dexcom has heard anything, even just rumors, about possible layoffs on the horizon? I'm in [Department, e.g., R&D/Sales/Operations] and things have felt... steady. But you never know. Company seems to be doing well, product pipeline looks strong, but market conditions can change fast. Just trying to get a pulse check before year-end. Anyone got any intel, even if it's just a gut feeling or a vague mention from a manager? Not trying to cause panic, just want to be prepared if things do shift. Appreciate any insights.
No more threads.